Head-to-head · free
Neurogene Inc. vs Novartis AG
NGNE vs NVS — return on capital, cash generation, margins and balance sheet side by side.
NGNE
0 / 2
measures where NGNE leads
NVS
2 / 2
measures where NVS leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | NGNE · FY2025 | NVS |
|---|---|---|
| Revenue | $0 | — |
| Net income | (90.4M) | — |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | (78.4M) | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | 18.6% |
| Return on equity | -31.4% | 31.0% |
| Gross margin | — | 75.8% |
| Operating margin | — | 31.1% |
| Net debt / EBITDA | 1.04x | 0.96x |
Figures are as reported by each company; latest fiscal year shown.
Where Neurogene Inc.'s cash went (FY2025)
- Capital spending
- $1.2M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free